|Printable version||E-mail this to a friend|
Cancer Research UK - Precision medicine trial first of its kind to show benefit to patients
A clinical trial for types of advanced cancer is the first of its kind to show that precision medicine – or tailoring treatment for individual people – can slow down the time it takes for a tumour to grow back, according to research presented at the Molecular Analysis for Personalised Therapy (MAP) conference(link is external), last week.
Results from the trial, which took place at the Gustave Roussy Cancer Campus(link is external) in Paris, found that 199 out of 1110 patients with advanced cancer, who had their genes mapped and their treatment tailored, had around 30 per cent longer before their cancer started growing again compared to any of the previous therapies the patients had tried. This ranged from between five and 32 months.
This trial involved patients who had no other treatment options left and who had already tried three or more cancer therapies. The team found potential faulty molecules to target for 411 of these patients and experimental drugs to hit the targets for 199 of these patients.
The patients on this trial had diverse types of advanced cancer including lung, breast, head and neck, prostate, bladder, bowel and stomach cancer.
The MAP conference is a joint initiative between Cancer Research UK, UNICANCER and ESMO.
Professor Jean Charles Soria, principal investigator of the trial from the Gustave Roussy Cancer Campus, said: “This is the first precision medicine trial to show that analysing a person’s DNA improves treatment options for patients with late stage cancer. And these results are particularly exciting because in some cases we were testing experimental drugs, and found that we could slow down the growth of tumours in around one in five patients with advanced cancer.”
Dr Christophe Massard, head of the early drug development multidisciplinary committee at Gustave Roussy, said: “The great thing about this is that it’s not just for one type of cancer - patients with many different types of cancer could benefit from this in the future.”
Dr Rowena Sharpe, head of precision medicine at Cancer Research UK, said: “This is an exciting time for precision medicine and personalised treatment. It’s fantastic to see continued effort going into this area and it’s important that we make the most of the data that we already have. The MAP meeting brings together expertise from across the globe to find the best ways to improve precision medicine programmes for cancer patients.”
For media enquiries please contact the Cancer Research UK press office on +44 203 469 8300 or, out-of-hours, the duty press officer on +44 7050 264 059.
Notes to Editor
The clinical trial is called MOSCATO 01
Latest News from
Age UK - Over half of lonely older people have never talked about it21/03/2017 13:35:00
Worrying figures revealed in Gransnet survey as the Jo Cox Commission on Loneliness launches its spotlight on older people month.
Cancer Research UK - Radiotherapy risks are much higher for smokers21/03/2017 12:35:00
Smokers treated for breast cancer have much higher risks than non-smokers of developing lung cancer or heart attack as a result of radiotherapy – according to a new study funded by Cancer Research UK and published yesterday in the Journal of Clinical Oncology
Age UK - Hike in calls to advice line over winter as more people seek help21/03/2017 08:35:00
Age UK saw a 12 per cent increase in calls to its national advice line from older people seeking help this winter compared to the same period last year, with enquiries about residential care the most frequent reason for getting in touch.
Cancer Research UK - 'Unacceptable' plans revealed by NICE that could delay availability of drugs on the NHS in England16/03/2017 11:35:00
Plans to create an additional affordability test for medicines available on the NHS have been labelled ‘unacceptable’ by charities and politicians.
Cancer Research UK to only contact supporters who have ‘opted in’ from 1 July 201715/03/2017 10:35:00
Cancer Research UK is to become an ‘opt in’ charity on 1 July 2017, meaning it will only contact supporters who have given unambiguous and explicit permission for the charity to contact them for marketing activity, including fundraising support.